Clinical trials in Zyrardow

9 clinical trials in Zyrardow, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PolandBadaniaKliniczne.pl

Zyrardow at a glance

clinical trials

Paediatric trials0
Research sites0

Quick filters

9 trials in Zyrardow

Open in trial search

Type 2 diabetes mellitus+2

Recruiting

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Registered drug

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Semaglutide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S

Contact Research Centre

Anaemia of chronic disease

Recruiting

Study on Efepoetin Alfa and Darbepoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis

Registered drugNo placebo

Study on Efepoetin Alfa and Darbepoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Darbepoetin Alfa
Sponsor:Genexine Inc.

Contact Research Centre

Type 2 diabetes mellitus

Not yet recruiting

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo

Poland

Participants:18–64 years
Substances:Insulin Glargine
Sponsor:Novo Nordisk A/S

Contact Research Centre

Anaemia of chronic disease

Not yet recruiting

Study on Efepoetin Alfa and Darbepoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis

Registered drugNo placebo

Study on Efepoetin Alfa and Darbepoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Darbepoetin Alfa
Sponsor:Genexine Inc.

Contact Research Centre

Cardiovascular disorder

Not recruiting

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Cagrilintide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Cardiac failure

Not recruiting

Evaluation of Ziltivekimab in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Investigational

Evaluation of Ziltivekimab in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Type 2 diabetes mellitus

Not recruiting

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Cagrilintide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Hyperparathyroidism secondary

Not recruiting

Study on the Effectiveness and Safety of PLS240 for Treating Secondary Hyperparathyroidism in Patients with End-Stage Kidney Disease on Hemodialysis

Investigational

Study on the Effectiveness and Safety of PLS240 for Treating Secondary Hyperparathyroidism in Patients with End-Stage Kidney Disease on Hemodialysis

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Upacicalcet Sodium Hydrate
Sponsor:Pathalys Pharma Inc.

Contact Research Centre

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Zyrardow

What the registry says about research in the country

01 Nephrology Research

Investigating treatments for patients with end-stage kidney disease (ESKD) and related complications, focusing on improving outcomes for those undergoing regular hemodialysis.

Secondary Hyperparathyroidism Management
Dialysis Treatment Optimization
Kidney Disease Complications

Current studies are evaluating novel therapeutic approaches for managing hormone imbalances in dialysis patients.

02 Hematology in Kidney Disease

Clinical research examining the effectiveness of different treatments for anemia in patients with chronic kidney disease requiring dialysis.

Anemia Management
Hemoglobin Level Control
Comparative Treatment Studies

Trials are comparing various erythropoiesis-stimulating agents to optimize anemia treatment in dialysis patients.

03 Chronic Disease Management

Comprehensive studies addressing multiple aspects of chronic kidney disease care, with emphasis on long-term treatment outcomes and quality of life improvements.

Treatment Efficacy Assessment
Long-term Safety Monitoring
Quality of Life Studies

Research focuses on developing more effective and safer treatment options for patients requiring ongoing dialysis care.

Back to Poland All countries